Targeted oligonucleotide conjugates

• US 6,300,319 B1
• Filed: 06/16/1998
• Issued: 10/09/2001
• Est. Priority Date: 06/16/1998
• Status: Expired due to Term

• Current Assignee: Ionis Pharmaceuticals, Inc.
• Original Assignee: ISIS Pharmaceuticals Incorporated
• Inventors: Manoharan, Muthiah
• Primary Examiner(s): Riley, Jezia
• Application Number:
  US09/097,753
• Time in Patent Office: 1,211 Days
• Field of Search: 435/6, 536/22.1, 536/23.1, 536/24.5, 536/25.3, 514/1, 514/44
• US Class Current: 514/44.00A
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention provides improved ingress of therapeutic and other moieties into cellular targets. In accordance with preferred embodiments, complexes are provided which carry primary moieties, chiefly therapeutic moieties, to such target cells. Such complexes preferably feature cell surface receptor ligands to provide specificity. Such ligands are preferably bound to primary moieties through polyfunctional manifold compounds.

Claims

1. A complex comprising:

a primary moiety for modulating a cellular function;

at least two cell surface receptor ligands; and

a manifold covalently connected to said primary moiety and each of said cell surface receptor ligands;

said manifold being a polycyclic molecule.

2. The complex of claim 1 further comprising a linking moiety covalently attaching said primary moiety to said manifold and further linking moieties covalently attaching each of said cell surface receptor ligands separately to said manifold.

3. The complex of claim 1 wherein said primary moiety is a nucleoside, nucleotide, an oligonucleoside, an oligonucleotide or a pro-drug form of said nucleoside, nucleotide, oligonucleoside or oligonucleotide.

4. The complex of claim 1 wherein each of said cell surface receptor ligands is the same.

5. The complex of claim 1 comprising at least three cell surface receptor ligands.

6. The complex of claim 1 having three cell surface receptor ligands which are the same.

7. The complex of claim 1 wherein said primary compound is a peptide, protein, a molecule that can bind RNA, an antibiotic or an antibacterial compound.

8. The complex compound of claim 1 wherein said polycyclic molecule comprises an aliphatic ring system, an aromatic ring system, a heterocyclic ring system, a mixed ring system having two or more aliphatic aromatic and heterocyclic rings connected or fused, wherein said polycyclic molecule also has a plurality of reactive sites thereon.

9. The complex of claim 1 wherein said manifold is cholic acid or a cholic acid derivative.

10. The complex of claim 1 wherein said cell surface receptor ligands are carbohydrates.

11. The complex of claim 10 wherein said carbohydrates are mono- or polysaccharides.

12. The complex of claim 11 wherein said saccharides are each galactose, lactose, N-acetylgalactosamine, mannose or mannose 6-phosphate.

13. The complex of claim 1 wherein said cell surface receptor ligands are each galactose or lactose.

14. A chemical complex having the formula:

wherein

said primary moiety is a nucleotide, nucleoside, oligonucleotide or oligonucleoside;

each of said linkers are, independently, bi- or trifunctional;

said manifold is derivatized at a plurality of sites, said manifold being a polycyclic molecule;

each of said cell surface receptor ligands is a carbohydrate; and

n is an integer from 2 to about 8.

15. The complex of claim 14 wherein said primary moiety is a nucleoside, nucleotide, oligonucleoside,oligonucleotide or a pro-drug form of said nucleoside, nucleotide, oligonucleoside or oligonucleotide.

16. The complex of claim 14 wherein there are at least three copies of the same cell surface receptor ligand.

17. The complex of claim 14 wherein said primary moiety is a peptide, protein, a molecule that can bind RNA, an antibiotic or an antibacterial compound.

18. The complex of claim 14 wherein said polycyclic molecule comprises an aliphatic ring system, an aromatic ring system, a heterocyclic ring system, a mixed ring system having two or more aliphatic aromatic and heterocyclic rings connected or fused, wherein said complex compound optionally has a plurality of reactive sites thereupon.

19. The complex of claim 14 wherein said manifold is cholic acid or a cholic acid derivative.

20. The complex of claim 14 wherein said cell surface receptor ligands are carbohydrates.

21. The complex of claim 20 wherein said carbohydrates are independently mono- or polysaccharides.

22. The complex of claim 21 wherein said saccharides are, independently, galactose, lactose, N-acetylgalactosamine, mannose or mannose 6-phosphate.

23. The complex of claim 14 wherein said cell surface receptor ligands are galactose or lactose.

24. The complex of claim 14 wherein n is from 2 to 6.

25. The complex of claim 14 wherein n is from 2 to 4.